Metrics as of 10/13/2026, 06:34 PM (Berlin time), refresh in progress.
Neumora Therapeutics Stock
Neumora Therapeutics, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Josh Pinto
- Employees
- 63
- Market cap
- $75 M
- IPO
- 15/09/2023
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa…
Neumora Therapeutics stock: price history
1D
-7.6%
1W
-14.2%
1M
-61.1%
6M
-80.1%
YTD
-77.4%
1Y
-78.3%
2Y
-97.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~30% weaker price swings than usual
Ask the agents about Neumora Therapeutics
Analyst assessment of Neumora Therapeutics
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.50
MEDIAN
US$4.50
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
6
BUY
1
HOLD
2
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 13/07/2026
Neumora Therapeutics stock metrics
P/E
-0.33
P/B
1.69
EV/EBITDA
0.2
RETURN ON EQUITY
-96.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
33.6%
FLOAT SHARES
62,287,188
AVG. DAILY VOLUME (30D)
1,746,826
Insider transactions (SEC)
Aurora Daljit Singh
Aurora Daljit Singh
Aurora Daljit Singh
Aurora Daljit Singh
Aurora Daljit Singh
Institutional holders
Comparable stocks
Frequently asked questions about Neumora Therapeutics stock
What does Neumora Therapeutics do?
Neumora Therapeutics, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Josh Pinto, the company employs around 63 people.
The IPO was on 15/09/2023; the stock trades on NASDAQ under the ticker NMRA.
What do analysts say about Neumora Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 13/07/2026).
The average price target is US$4.50, ranging from US$4.00 to US$5.00, with a median of US$4.50.
This is an external assessment, not a statement by Market Jury.
When does Neumora Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -30% stronger than usual.
Does Neumora Therapeutics pay a dividend?
No, Neumora Therapeutics currently does not pay a dividend.
Which stocks are comparable to Neumora Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Neumora Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Neumora Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.